2140P - Short-term quality-of-life after metastases-directed SBRT: Results of the prospective ESTRO & EORTC OligoCare cohort

Background

Metastases-directed stereotactic body radiotherapy (SBRT) in addition to standard of care systemic therapy is supported by randomized phase II trials and international practice guidelines for patients with an oligometastatic disease (OMD). However, little is known about quality of life (QoL) following SBRT, which would be valuable to better inform patient and clinicians in their decision-making process about the optimal multimodality treatment strategy.

Methods

OligoCare is a pragmatic prospective cohort study of E²-RADIatE, a collaboration between ESTRO and EORTC, which aims to identify patient, tumour, and treatment characteristics influencing overall survival after ablative radiotherapy for oligometastatic breast, colorectal, lung and prostate cancer. Patients are eligible irrespective of oligometastatic state (de-novo, repeat or induced), without restrictions to local or systemic therapy. Radical radiotherapy must be a component of treatment, irrespective of maximum number of metastases, as long as all cancer lesions are treated with radical intent. Assessment of QoL using the EORTC QLQ-C30 is optional. This analysis reports QoL at baseline and first FU (3-12 months) on the first 1600 enrolled patients.

Results

530 patients completed baseline QoL and 399 completed follow-up (median time after SBRT: 6 months). 71% of patients were male, with oligometastatic prostate cancer the most frequent primary (45%), followed by NSCLC (24%), breast (17%) and colorectal cancer (14%). WHO performance status was 0 or 1 in 87% of patients, median age was 69 years and median one single oligometastasis was treated with SBRT (range 1-8). Average global health status at baseline was 72 (SD 19.5), with higher baseline QoL in prostate cancer (average 78) as compared to NSCLC (average 65) or breast cancer (average 68) patients. Global health status remained stable during follow-up (average 72; SD 20), without differences between primary diseases. A more detailed assessment of QoL subdomains is underway.

Conclusions

Collection of QoL data was feasible in this prospective registry and early QoL remained stable following metastases-directed SBRT in oligometastatic breast, colorectal, lung and prostate cancer.

Clinical trial identification

NCT03818503.

Editorial acknowledgement

Legal entity responsible for the study

European Organisation for Research and Treatment of Cancer - EORTC.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.